Since antibody-based therapeutics that either bind directly to IL-6 or block the effect of IL-6 by binding to its receptor are already in use for inflammatory and rheumatologic disorders [177,178], several clinical trials have tested this approach (NCT04333706, NCT04940299, and NCT02644967). The gene discussed is IL6; the disease is rheumatic disorder.